In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals in Depth: October 2010

Executive Summary

Teaming up for the sixth time, Exelixis penned a $545 million deal with BMS for early-stage type 2 diabetes and inflammation candidates. Stryker/Boston Scientific's neurovascular business and St. Jude/AGA Medical were the two billion-dollar acquisitions in devices. Biopharma financing hugely increased to over $2 billion in October. Device fundraising reached $280 million, almost exactly as much as September's total.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts